Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762935 | 0.85 | ALDH1A1 (0.47) | PTGDR2ALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL2763284 | 0.83 | PTGS2 (0.46) | PTGDR2ALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL2762555 | 0.82 | PTGS2 (0.48) | PTGDR2ALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL2763243 | 0.81 | PTGS2 (0.47) | PTGDR2ALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL14010506 | 0.80 | PTGS2 (0.46) | PTGDR2ALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL15929208 | 0.79 | PTGS2 (0.51) | PTGDR2ALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL554801 | 0.79 | KDM4E (0.55) | ALDH1A1HPGDHTTMAPTLMNA | |
| SCHEMBL2762817 | 0.78 | PTGS2 (0.45) | PTGDR2ALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL7363630 | 0.76 | ALDH1A1 (0.70) | PTGDR2ALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL2763259 | 0.76 | PTGDR2 (0.41) | PTGDR2ALDH1A1HPGDSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8303978-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8303978-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOCHEMICAL, LLC (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOCHEMICAL, LLC (US) | 2012-02-09 | — | — | US | disclosed |
| EP-2398761-A2 | CONTROLLED RELEASE OF NITRIC OXIDE AND DRUGS FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS | Bezwada Biomedical, LLC (US) | 2011-12-28 | — | — | EP | disclosed |
| US-8062653-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-8062653-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010096320-A2 | CONTROLLED RELEASE OF NITRIC OXIDE AND DRUGS FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOMEDICAL, LLC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOMEDICAL, LLC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | PTGDR2 199/4885ALDH1A1 676/4885HPGD 69/4885 |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | PTGDR2 199/4885ALDH1A1 676/4885HPGD 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.